Perhaps this is why the AS deal was so small. Why invest 10’s of millions on a small indication for B when in all likelihood will be obsolete with oral dosage soon to be tested. Seems like they made a minimal investment for UP by chance that oral dosage didn’t work.
Yep, and if we get a strong 2b it is off to the races. So many good things could happen, it is not worth the electrons to detail them, as all longs have the litany memorized by now.